

Speakers Bureau for Roche. Dr. Paul has received personal compensation in the range of \$500-\$4,999 for serving on a Speakers Bureau for Pfizer. Dr. Paul has received personal compensation in the range of \$500-\$4,999 for serving on a Speakers Bureau for Merck Serono. The institution of Dr. Paul has received personal compensation in the range of \$500-\$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. Dr. Levy has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Levy has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for UCB Pharma. Dr. Levy has received personal compensation in the range of \$5,000-\$9,999 for serving as a Consultant for Sanofi. Dr. Levy has received personal compensation in the range of \$5,000-\$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Levy has received personal compensation in the range of \$5,000-\$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Levy has received personal compensation in the range of \$5,000-\$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Levy has received personal compensation in the range of \$500-\$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Levy has received personal compensation in the range of \$10,000-\$49,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Levy has received research support from National Institutes Health.

### FDA Approved Treatments for Neuromyelitis Optica Spectrum Disorder in Clinical Practice: A Survey of Academic Neuroimmunologists

Jesse Thon, Robert Sharkus, Richa Thakkar, Krystal Hunter, James Siegler, Olga Thon

#### Objective

To assess utilization and barriers to use of three recently FDA-approved treatments for neuromyelitis optica spectrum disorder (NMOSD) by academic neuroimmunologists.

#### Background

Since 2019, eculizumab, inebilizumab, and satralizumab have received FDA approval for the treatment of aquaporin-4 IgG positive (AQP4+) NMOSD after showing efficacy in reducing attack frequency. However, little is known regarding the adoption of these therapies into practice or barriers to their use. We conducted a survey of academic neuroimmunologists to identify current treatment practices.

#### Design/Methods

An electronic survey study was conducted of US neuroimmunologists. Recipients were identified on department websites of university-associated hospitals with affiliated neurology residencies. The survey was administered via email, and included questions regarding clinical background, patient cohort, treatment use in different scenarios, and barriers. The authors were blinded to the identity of respondents.

#### Results

383 neuroimmunologists from 105 institutions were identified, of whom 33 from 18 states completed the survey. Nearly all (88%) reported treating patients with the newly FDA-approved therapies (NFTs). None reported discomfort discussing any NFT with their patients. Respondents reported uncommonly switching clinically stable patients to NFTs (69% never switch, 22% switch 1-25% of the time). For newly diagnosed AQP4+ NMOSD patients, NFT initiation rates varied (16% initiate none, 42% 1-25% of the time, 6.5% 25-50%, 19% 50-75%, 16% 75-100%). For patients with a relapse, responses were dichotomized regarding switching to NFTs - respondents either switch 75-100% of their patients (60%) or none or 1-25% (16%, 24% respectively). Nearly half (16/33) of respondents reported being unable to start NFTs, with insurance/cost issues being the most cited barrier.

#### Conclusions

Among academic neuroimmunologists, FDA-approved therapies for AQP4+ NMOSD are being utilized for newly diagnosed patients and those

with disease recurrence, although individual practice patterns vary. The main perceived barriers to NFT use are insurance/cost-related issues.

**Disclosure:** An immediate family member of Dr. Thon has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Horizon. An immediate family member of Dr. Thon has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Genentech. An immediate family member of Dr. Thon has received personal compensation in the range of \$500-\$4,999 for serving on a Speakers Bureau for Genentech. Dr. Thon has received personal compensation in the range of \$500-\$4,999 for serving as a Focus group participant with Alexion. Dr. Sharkus has nothing to disclose. Dr. Thakkar has nothing to disclose. Krystal Hunter has nothing to disclose. Dr. Siegler has received personal compensation in the range of \$10,000-\$49,999 for serving as a Consultant for Ceribell. Olga Thon has nothing to disclose.

### Safety and Effectiveness of Eculizumab in Japanese Patients With Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance Study

Ichiro Nakashima, Yo Hoshino, Kazumi Okamura, Hidekazu Kikui, Kazuo Fujihara, Yuriy Edwards

#### Objective

NA.

#### Background

The terminal complement C5 inhibitor eculizumab is approved in Japan for the prevention of aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) relapse and undergoing mandatory post-marketing surveillance (PMS) of real-world use.

#### Design/Methods

This PMS interim analysis assessed eculizumab's safety and effectiveness in Japanese patients AQP4+ NMOSD patients from approval (November 2019) to interim data cut-off (1 April 2021).

#### Results

At data cut-off, 79 patients treated with eculizumab were registered under PMS. Data were available for 20 patients who provided consent for publication and constituted the safety data set; three patients from the phase 3 PREVENT study were excluded from the effectiveness data set. Two patients discontinued before data cut-off owing to physician or patient decision (one each). In the effectiveness data set, 16/17 (94%) patients were female, mean illness duration was 9.2 years (standard deviation [SD] 7.5 years, range 0.3–23.8 years) and mean age at eculizumab initiation was 48.6 years (SD 11.9 years, range 27–77 years). In the 2 years before eculizumab, 12/17 patients experienced relapse, and 6/17 experienced =2 relapses. Importantly, no relapses were reported in the effectiveness data set (10.7 patient-years [PY] of treatment); this compared favorably with a 0.65/PY relapse rate in the 2 years before treatment (34.0 PY). Three adverse events (malaise, eyelid oedema, erythema) and one serious adverse event (urinary tract infection [UTI]) were observed in three patients in the safety data set: eyelid oedema and erythema (one patient) were deemed treatment-related; malaise and UTI were deemed unrelated to treatment. No meningococcal infections were reported, and the safety results were consistent with those from PREVENT.

#### Conclusions

For the first time in a real-world setting, eculizumab was effective in preventing relapses and well tolerated in Japanese patients with AQP4+ NMOSD, consistent with its efficacy and safety profile in the global phase 3 PREVENT study.

**Disclosure:** Dr. Nakashima has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Nakashima has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board

# Neurology®

## FDA Approved Treatments for Neuromyelitis Optica Spectrum Disorder in Clinical Practice: A Survey of Academic Neuroimmunologists

Jesse Thon, Robert Sharkus, Richa Thakkar, et al.

*Neurology* 2022;99;S2

DOI 10.1212/01.wnl.0000903060.69682.6b

**This information is current as of December 5, 2022**

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/99/23_Supplement_2/S2.1.full">http://n.neurology.org/content/99/23_Supplement_2/S2.1.full</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>Cerebrospinal Fluid</b> <a href="http://n.neurology.org/cgi/collection/cerebrospinal_fluid">http://n.neurology.org/cgi/collection/cerebrospinal_fluid</a> <b>CT</b> <a href="http://n.neurology.org/cgi/collection/ct">http://n.neurology.org/cgi/collection/ct</a> <b>Low pressure syndrome</b> <a href="http://n.neurology.org/cgi/collection/low_pressure_syndrome">http://n.neurology.org/cgi/collection/low_pressure_syndrome</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2022 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

